Sign In
Buy RHHBY
$49.06
-0.130 (-0.264%)
At Close: Jun 03, 2026
BOSTON--(BUSINESS WIRE)--Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery coupled with direct-to-vivo measurement, today announced a strategic research collaboration a
Positive Phase III Data for Genentech's Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
01:00am, Monday, 03'rd Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from the
Basel, 3 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the phase III ALLEGORY study of Gazyva®/Gazyvaro® (obinut
Roche purchases shares in tender offer for 89bio, Inc
02:00am, Thursday, 30'th Oct 2025
Basel, 30 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche's wholly owned subsidiary Bluefin Merger Subsidiary, Inc., has accepted for payment all shares validly tendered a
Pat Roche Elected to The EMCOR Group, Inc. Board of Directors
08:00am, Wednesday, 29'th Oct 2025
NORWALK, Conn.--(BUSINESS WIRE)--EMCOR Group, Inc. (the “Company”) (NYSE: EME) announced today the election of Pat Roche to the Company's Board of Directors, effective October 27, 2025. Mr. Roche,
Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue
02:00am, Wednesday, 29'th Oct 2025
Basel, 29 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE mark for its Elecsys® Dengue Ag test – a high-throughput, fully automated immunoassay to be used
Positive Phase III Results for Genentech's Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome
02:00am, Tuesday, 28'th Oct 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the P
Roche Holding AG (RHHBY) Q3 2025 Sales Call Transcript
06:47pm, Thursday, 23'rd Oct 2025
Roche Holding AG (OTCQX:RHHBY) Q3 2025 Sales Call October 23, 2025 8:00 AM EDT Company Participants Thomas Schinecker - Group Chief Executive Officer Alan Hippe - Chief Financial Officer Teresa Graham
RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised
10:06am, Thursday, 23'rd Oct 2025
Roche's Q3 sales climbed 6% to CHF 14.9B, powered by surging demand for Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus.
Roche Raises Full-Year Earnings Outlook
01:45am, Thursday, 23'rd Oct 2025
The pharma group lifted its guidance citing strong results to date, and reported a rise in sales excluding currency movements.
Changes to the Roche Enlarged Corporate Executive Committee
01:30am, Thursday, 23'rd Oct 2025
Basel, 23 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Nina Schwab-Hautzinger (1975) has been appointed Head of Group Communications and a member of the enlarged Corporate Ex
Roche raises guidance on forecast-beating nine-month sales
01:08am, Thursday, 23'rd Oct 2025
Swiss drugmaker Roche on Thursday lifted its full-year guidance after reporting nine-month sales that were better than expected.
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
04:44pm, Tuesday, 21'st Oct 2025
Roche Holding AG (OTCQX:RHHBY) Shareholder/Analyst Call October 21, 2025 11:00 AM EDT Company Participants Bruno Eschli - Head of Investor Relations Nilesh Mehta - Global Franchise Head - Ophthalmolog
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis
10:36am, Tuesday, 21'st Oct 2025
RHHBY secures FDA approval to expand Gazyva's label for treating lupus nephritis, offering patients a faster and more convenient treatment option.
My Top 3 Pharma Stocks
11:38am, Monday, 20'th Oct 2025
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and o
